Treatment of chronic hepatitis C genotype 3 (GT3) is more challenging compared with other genotypes. Since 2014, several new treatment regimens have been approved but sometimes based on limited data.
SUMMARY Background
Treatment of chronic hepatitis C genotype 3 (GT3) is more challenging compared with other genotypes. Since 2014, several new treatment regimens have been approved but sometimes based on limited data.
Aim
To validate the use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection under real-word conditions.
Methods
The German Hepatitis C-Registry is a large national non-interventional real-world study for patients with chronic hepatitis C. A total of 1322 GT3 patients were enrolled (211 untreated and 1111 treated patients).
Results
Between February 2014 and September 2015, five different treatment strategies have been used (PegIFN+RBV, PegIFN+RBV+SOF, SOF+RBV, DCV+SOFAERBV, LDV/SOFAERBV). Treatment uptake and use of treatment concepts changed markedly and rapidly during the study influenced by new approvals, guideline recommendations, and label updates. PegIFN-based therapies constantly declined while DCV-based therapies increased with one interruption after the approval of LDV/SOF, which was frequently used until new guidelines recommended not using this combination for GT3. Per-protocol SVR ranged from 80.9% in the PegIFN+RBV group to 96.1% in PegIFN+RBV+SOF treated patients. Treatment-experienced patients with cirrhosis showed a suboptimal SVR of 68% for SOF+RBV but a high SVR of 90-95% for DCV+SOFAERBV. The safety analysis showed more adverse events and a stronger decline of haemoglobin for RBV containing regimens.
Conclusions
Real-world data can validate the effectiveness and safety for treatment regimens that had previously been approved with limited data, in particular for specific subgroups of patients. The present study demonstrates how rapid new scientific data, new treatment guidelines, new drug approvals and label changes are implemented into routine clinical practice today. INTRODUCTION Chronic hepatitis C is associated with significant morbidity and mortality which can be reduced by anti-viral treatment. [1] [2] [3] Recently, hepatitis C therapy has been revolutionised with the introduction of direct acting antivirals (DAA), which lead to a sustained virological response (SVR) in >90% of patients. 4 However, several new DAA have only limited activity against genotype 3 (GT3), which thus remains a challenge. 5 In addition, GT3 infection is associated with higher risks of cirrhosis and hepatocellular carcinoma. 6 In January 2014, sofosbuvir (SOF) was approved by the European Medicines Agency (EMA) to become the first DAA that could be effectively used for GT3. SOF plus ribavirin (RBV) resulted in a SVR of 85% in the phase III trials. However, treatment-experienced patients with cirrhosis showed only a SVR of 62%. 7 This was a reason why the combination of SOF, RBV and pegylated interferon alfa (PegIFN) given for 12 weeks was still considered in patients with GT3 although data were initially limited. 8 Daclatasvir (DCV) was approved by the EMA in August 2014 also for GT3 although corresponding data just came from a small phase II trial. 9, 10 Only in September 2015, the results of the phase III trial ALLY-3 11 and the European compassionate use programme 12 led to an extended GT3 label for DCV to treat noncirrhotic patients for 12 weeks with DCV+SOF. In November 2014, the fixed dose combination ledipasvir/sofosbuvir (LDV/SOF) was approved by the EMA. In contrast to the Food and Drug Administration (FDA), EMA approved LDV/SOF also for GT3. Treatment with LDV/SOF+RBV was recommended for 24 weeks in GT3 patients with cirrhosis or previous treatment failure. However, there were only limited data from 101 patients who had been treated in phase II trials with LDV/SOF with or without RBV for 12 weeks. 13 Thus, treatment options for GT3 have changed significantly in a short time period between 2014 and 2016 while treatment recommendations were based on limited evidence.
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METHODS AND PATIENTS
German Hepatitis C-Registry and patient population The German Hepatitis C-Registry (Deutsches Hepatitis C-Register, DHC-R) is a multicentre, non-interventional registry study. Patient data were recorded via a web browser based Electronic Data Capture (EDC) system without software installation on site (BEO, e.factum GmbH) hosted at a Clinical Research Organization (CRO). Data quality was reviewed by study monitors via plausibility checks to assure completeness and accuracy. Furthermore, queries were issued to verify or resolve unlikely and/or extreme values. On-site monitoring was conducted in randomly selected sites and when queries had to be solved.
Patient enrolment started on 24 November 2014. The registry is prospective but data could be documented up to 3 months retrospectively. A prolonged retrospective documentation period was allowed to record anti-viral therapies, which started on or after 1 February 2014 in order to prevent bias due to non-inclusion of patients treated with DAAs, which received marketing authorisation in Europe before 24 November 2014 [SOF, DCV, LDV and Simeprevir (SMV)].
The present analysis is based on 8878 patients documented until 30 June 2016. The screening cohort consists of patients, which were not treated until 30 June 2016. The treatment cohort includes patients who started anti-viral therapy on or before 30 September 2015. For the safety and effectiveness analysis of GT3 patients, patients with genotypes other than GT3 or with two different genotypes were excluded.
Assessment of endpoints
The safety population (Intention-To-Treat1, ITT1) consists of patients who started anti-viral therapy and in whom at least the baseline visit was documented. ITT2 refers to the EoT population (patients who have a documented end of treatment). The modified intention-totreat effectiveness analysis (ITT3) considered only ITT2 patients who should have completed follow-up 12 weeks after EoT on 30 June 2016. For the per-protocol analysis (PP) the following ITT3 patients were excluded: noncompliant patients, patients with missing data or patients lost to follow-up.
Primary endpoint was the proportion of patients, who achieved SVR12. SVR12 was defined as HCV-RNA lower limit of quantification 70-153 days after EoT. This definition was used because timing of patient visits varies under real-world conditions. In the present study, SVR12 data are shown for the ITT3 and PP populations.
Definitions
Duration of therapy: Therapies up to 98 and ≥141 days were defined as '12 weeks' and '24 weeks' respectively. A therapy lasting 99-140 days was considered as 'other duration'.
Liver cirrhosis was defined by one of the following criteria: biopsy showing cirrhosis (Metavir score F4), transient elastography (Fibroscan, Echosens, France) >12.5 kPa, ultrasound confirming cirrhosis, clinical evidence of cirrhosis (e.g. presence of ascites, oesophageal varices).
Statistics
Due to the ongoing nature of the study, the status of data for this analysis was frozen on 30 June 2016 including all queries answered by 26 July 2016.
Summary statistics, frequencies and proportions were assessed dependent on the scale level of the data. In advance, all relevant variables needed to describe the GT3 sample were defined in a statistical analysis plan. Differences in specific baseline demographic and clinical characteristics between patients only screened and patients treated, and differences in the occurrence of adverse events in-patient groups treated with regimens with or without ribavirin were compared statistically using two-sided hypothesis t-test or Pearson v² test (indicated in tables) depending on the scale level. Univariate and multivariate analyses [logistic regression model (LR), with 95% confidence intervals for the odds ratio (OR) and response rates were calculated (not done for constant values)]. Differences were considered relevant for P ≤ 0.05. Analyses were calculated using SPSS Windows Release 22.0.0.2 (IBM Corporation, New York, US).
Role of the funding source
The authors are independent from the funding companies in data analysis, data interpretation, report writing and publication.
RESULTS
Patients and use of treatment regimens A total of 1322 patients with chronic hepatitis C GT3 were enrolled at 196 sites (Figure 1a,b) . From 1 February 2014 until 30 September 2015, 211 patients were screened but not treated while 1111 patients started therapy ( Figure 1a) . Baseline characteristics are shown in Table 1 . When compared with treated patients, nontreated patients were younger, had less frequently liver cirrhosis, and more frequently inject(ed) drugs with opiate substitution treatment.
From 1111 patients who started treatment (safety population), 845 patients should have completed the followup 12 weeks after EoT (effectiveness population, ITT3). However, in 104 cases data were incomplete, or patients were lost to follow-up. Thus, the per-protocol analysis (PP) consists of 741 patients ( Figure 1a) . The proportion of different treatment regimens in the three different patient populations is shown in Figure 2a . Eleven patients received inconclusive anti-viral therapies that will be referred to as 'other' therapies:
The proportion of the treatment regimens that have been used showed strong fluctuations during the 20 months study period. Figure 2b shows these proportions with the total study duration separated into five time periods. Dual PegIFN+RBV, which was the standard therapy for GT3 until January 2014, was only used during the first periods. PegIFN+RBV+SOF was the main regimen until the approval of DCV and showed a continuous decline after the approval of LDV/SOF. LDV/SOF was only used in the third period until the update of the EASL guidelines in April 2015. SOF+RBV was the only regimen with a rather constant use but its use declined after the update of the DCV label for GT3. Effectiveness of treatment Table 2 shows SVR12 results for the effectiveness (ITT3) and per-protocol (PP) cohorts. SVR12 in the ITT3 analysis ranged from 59.1% in the PegIFN+RBV group to 90.4% in PegIFN+RBV+SOF treated patients. The SVR12 in the PP analysis ranged from 80.9% in the PegIFN+RBV group to 96.1% in PegIFN+RBV+SOF treated patients. DCV+SOFAERBV showed the second best SVR12 rates in the ITT3 and PP analysis with 87.8% and 93.1%, respectively. However, the frequency of cirrhosis in patients receiving DCV+SOFAERBV (33.5%) was considerably higher when compared to the PegIFN+RBV+SOF group (22.1%). The rate of early treatment discontinuations was highest in the PegIFN+RBV group with 18.3% followed by 24 weeks of treatment with SOF+RBV. SOF+RBV, the first IFN-free therapy, resulted in 84.1% SVR. However, IFN-pretreated patients with cirrhosis showed a SVR of only 68% in the PP analysis when re-treated with SOF+RBV ( Figure 3b ). For a more detailed analysis, the DAA regimens were further categorised based on recommended treatment duration and use of RBV. Treatment duration that did not match the definition of the protocol was not included in the analysis (n = 118). Baseline characteristics showed strong differences between the different groups. As expected, the DCV+SOF+RBV 24 week cohort consists of more patients with cirrhosis (81.7%) compared to the DCV+SOF 12 week cohort (6.5%). Detailed information is given in Table 3 . We observed differences in SVR12 among different patient categories defined by cirrhosis and pretreatment (Figure 3a ,b, Tables S1 and S2, published online). Univariate analysis for the PP data revealed that cirrhosis was the main predictor for SVR12 (<0.05). For visualisation of the PP SVR12 data in the different regimens, we only included data if ≥10 patients were included (Figure 3a,b) . For patients without cirrhosis, PP SVR12 data were >90% with PegIFN+RBV+SOF, DCV+SOF 12 weeks, and DCV+SOF+RBV 12 weeks, respectively. Na€ ıve and IFN treatment-experienced noncirrhotic patients did not show different response rates. However, there was a 3% higher SVR12 rate in treatment-na€ ıve patients vs. IFNexperienced patients treated with 12 weeks DCV+SOF (Figure 3a ). For patients with cirrhosis, PP SVR12 data were >90% with DCV+SOF+RBV 12 weeks, DCV+SOF+RBV 24 weeks and LDV/SOF+RBV 24 weeks, respectively. Detailed analyses are shown in Table S1 and S2, published online.
Safety of treatment
Overall, 721 adverse events (AEs) and 48 serious adverse events (SAEs) were reported in the safety population (Table 4 ). There were significantly less AEs in the DAA groups that did not contain PegIFN and/or RBV (P < 0.001). The frequency of fatigue was 36.2-45.1 in PegIFN+RBV containing therapies and 32.5-45.0% in PegIFN free but RBV containing DAA regimens, but only 0-25% in PegIFN+RBV free regimens (Table S3, published online). As expected, RBV containing regimens demonstrated a more pronounced reduction in haemoglobin compared to RBV free regimens (Figure 4) .
The frequency of AEs did not show strong differences between 12-or 24-week DAA regimens, which did not include RBV. However, some of the AEs occurred more frequently in the RBV containing regimens given for 24 weeks when compared to those given only for 12 weeks. Thus, RBV dose reduction occurred more often in the 24-week regimens compared with the 12-week regimens (i.e. 24 weeks SOF+RBV 6.5%, 12 weeks DCV+SOF+RBV 0%, 24 weeks DCV+SOF+RBV 11.7%). However, RBV discontinuation was rare, i.e. only five SOF+RBV treated patients and only four DCV+SOF+RBV treated patients discontinued RBV. RBV discontinuation had more impact on the SOF+RBV cohort as only one patient achieved SVR. In contrast, all four patients who stopped RBV in the DCV+SOF+RBV group attained SVR. Interestingly, the frequency of AEs was similar between patients receiving PegIFN+RBV+SOF for 12 weeks and those receiving SOF+RBV for 24 weeks. Importantly, only two of PegIFN+RBV+SOF treated patients discontinued PegIFN. Both patients continued SOF+RBV for a total of 20 or 24 weeks, respectively, and achieved SVR. The cohort treated for 24 weeks with DCV+SOF+RBV had the highest frequency of AEs and the second highest of SAEs (Table 4) . However, the number of patients with advanced liver cirrhosis was higher in that group; that is, 28.3% had platelets <90/nL (Table 3) . * ITT2 (n = 920). Early termination of therapy due to an SAE was reported in seven patients among all treatment groups [PegIFN+RBV+SOF (n = 1), SOF+RBV (n = 2), DCV+SOFAERBV (n = 4)]. † Effectiveness population. ‡ SVR12 (PP) was significantly associated with age (P = 0.002), gender (P = 0.004), cirrhosis (P = 0.009), baseline albumin (P = 0.023) and baseline platelets (P = 0.011) in univariate regression analysis. § Other treatment regimens were rare, inconclusive and not included in the interpretation of data.
DISCUSSION
Treatment of chronic hepatitis C has markedly been improved with the introduction of IFN-free DAA therapies in 2014. In contrast to genotype 1, there have still been more challenges for treatment of patients with GT3. 5 Several DAA had not been approved for GT3 and for several combinations, that is, PegIFN+RBV+SOF, DCV+SOF+RBV and LDV/SOF+RBV data had been limited. [8] [9] [10] 13 The present real-world study shows that the use of DAA combinations has significantly changed several times within a short period of 20 months. Despite the approval of SOF+RBV in January 2014, 22% of patients still received dual PegIFN+RBV in the first time period of the present study. More than 93% of patients treated with PegIFN+RBV at that time were therapy-na€ ıve patients without cirrhosis. In fact, response-guided therapy with PegIFN+RBV for 16-24 weeks in therapy-na€ ıve noncirrhotic patients was at that time a reasonable alternative compared to 24 weeks SOF+RBV in particular when considering costs. 14 The most frequently used regimen with >50% of all patients treated during the first 7 months after approval of SOF was 12 weeks PegIFN+RBV+SOF. Interestingly, this treatment showed numerically the best SVR among all regimens. Thus, the present real-world data confirms the efficacy of PegIFN+RBV+SOF reported in the BOSON phase III trial 15 and is in line with other recent realworld data. 16, 17 Based on our data, treatment with PegIFN+RBV+SOF for 12 weeks can achieve a PP SVR >95% in patients without cirrhosis and a SVR >85% in patients with cirrhosis. Thus, this combination is an effective option if other DAA are not available or not recommended due to economical considerations, which is the reality in many countries up to now, i.e. in Poland. 18 After the approval of DCV, the use of PegIFNbased therapies declined constantly in this German study probably also because the German Guidelines published in October 2014 recommended not to use IFN anymore. 19 Despite limited data for GT3, uptake for DCVbased therapies was fast and reached almost 50% in the 3 months period following EMA approval and more than 80% after the label update for noncirrhotic patients. More than 120 noncirrhotic patients have been treated with the recommended 12 weeks DCV+SOF regimen. The SVR of 93% was comparable to the result from the ALLY3 phase III trial.
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However, 12 week DCV+SOF+RBV reached even 100% SVR in patients without cirrhosis. In general, RBV should be avoided if possible because it is associated with a higher frequency of AEs and anaemia as confirmed in this study. For GT3 it may, however, remain a cornerstone, if baseline NS5A resistant associated substitutions (RAS) are present 20 or patients have unfavourable baseline characteristic. This appears to be true even for the recently approved combination of velpatasvir and sofosbuvir (VEL/SOF), which has become another new standard therapy for GT3. 21, 22 The current EASL clinical practice guidelines recommend treating IFN treatment-experienced GT3 patients treatment-experienced but 42% of 12-week DCV+SOF+RBV treated patients.
Patients with well-compensated compensated cirrhosis achieved excellent SVR with 12 weeks DCV+SOF+RBV like in the ALLY3+ trial 24 although the number of cirrhotic patients treated with this regimen was small in the present registry. For patients with advanced cirrhosis, we suggest 24 weeks DCV+SOF with or without RBV; the SVR was nominally higher in the RBV containing cohort but the limitations of a non-interventional registry have to be considered before recommending to add RBV in all patients with advanced cirrhosis. However, addition of RBV with a rapid dose reduction in the case of AEs may be a reasonable approach.
Costs and availability will remain major factors for the decision between a one-pill-fits-all concept and an individualised approach. 25 However, economic considerations can be problematic if newly approved therapies are used too fast without robust data available. This had been the case for the use of LDV/SOF, which had a lower price, compared with the use of DCV+SOF. After the approval of LDV/SOF there was a rapid uptake in the real-world setting accounting for almost 30% of all GT3 therapies although the study data were based on limited phase II data showing a SVR between 64 and 100%. 13 However, not a single patient in recent studies received LDV/SOF+RBV for 24 weeks as recommended in the label. Our data show that treatment with LDV/SOF+RBV for just 12 weeks is suboptimal and only reaches the SVR seen with SOF/RBV. Our present data are similar to the data of the UK early access program (EAP), which showed a SVR of only 61% for 12 weeks LDV/SOFAERBV in patients with advanced cirrhosis. 26 Interestingly, sequence analysis of GT3-infected patients with failure to LDV/SOF-based therapy from a large European Resistance Databank showed no selection of NS5A RAS. 27 This indicates a low anti-viral activity of LDV against GT3 isolates. However, patients treated according to the label for 24 weeks with LDV/SOF+RBV showed a SVR >90% in difficult-to-treat patients, which may be explained by some additional efficacy of the administration of LDV, if given for a longer period despite a low anti-viral activity against GT3. Retrospectively, the label recommendation proved to be appropriate but a treatment period of 24 weeks with LDV/SOF+RBV may only be considered if no other NS5A inhibitor is available. One more interesting aspect of our data is that the use of LDV/SOF dramatically declined after the International Liver Congress of EASL in 2015 at which the UK EAP data and the new EASL guidelines recommended not to use LDV/SOF in GT3. 28 This clearly demonstrates the importance of scientific meetings and guidelines for the real-world setting and also shows how rapid such recommendations are implemented into clinical practice today.
One important aim of the real-world registry was to validate the data of treatment with SOF+RBV for 24 weeks, which became available as the first IFN-free therapy for GT3 after the approval of SOF in January 2014. However, SOF+RBV was only used in approximately one quarter of patients and this figure did not show dramatic changes over time. The uncertainty of data in difficult-to-treat patients and the high costs were probably main reasons for the hesitant use of SOF+RBV. In fact, our data confirm that the SVR is suboptimal for that regimen in IFNexperienced patients with cirrhosis. This observation was similar in other real-world studies. 16, 17 Thus, SOF+RBV should not be used if VEL/SOF or DCV+SOF are available. The suboptimal effectiveness of SOF+RBV in difficultto-treat patients and the lack of robust data for other therapies might be a reason why treatment has been delayed in GT3 patients more often when compared with GT1 patients in the present German cohort. The frequency of patients who were screened but not treated was higher for GT3 when compared with the non-GT3 cohort. In addition, GT3 patients were underrepresented in this study with around 15% of all HCV patients when compared with 28% seen in a former large German reallife registry. 29 Patients in the nontreated cohort were younger and more often treatment-na€ ıve; they also had less frequently cirrhosis but more frequently had an opiate substitution therapy. These characteristics may have been reasons to delay treatment until more reliable data or better treatment options became available. Indeed, shortly after the GT3 12 week label update of DCV the frequency of nontreated patients dropped from 18% to 4%.
A strength of the present study is the fact that it included almost 200 sites with many of them treating <10 patients. Thus, the present registry reflects not a multicentre study of academic centres but a true realworld cohort covering more than 30% of all therapies initiated in Germany during that time period. The present study shares the limitations of all real-world studies with data not as complete and controlled when compared with phase II/III studies.
In conclusion, the present analysis shows that realworld data can validate the effectiveness and safety for treatment regimens that had previously been approved with limited data in particular for subgroups of patients. The present study also demonstrates how rapid new scientific data, new treatment guidelines, new drug approvals and label changes are implemented into routine clinical practice today.
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